An experimental weight-loss pill from Eli Lilly helped people lose up to about 12% of their body weight, a new study found, potentially clearing the way for the drug to be on the market next year https://t.co/eihfsfp4I8 ...

Eli Lilly was nearly a $1 trillion company. Now it’s facing missed targets, tariff threats and investor doubts https://t.co/CW1FkuGaUS ...

Eli Lilly’s weight-loss drug underperformed in trials, sending its shares down and boosting Novo Nordisk’s stock https://t.co/UxkQixYEBD ...

Stock Performance - Lilly's stock experienced a decline in early trading [1] Pharmaceutical Products - Disappointing data on Lilly's new weight-loss pill was released [1] - The company experienced strong growth from its marketed obesity medicine [1]

August 7, 2025 For release: Immediately Refer to: Ashley Hennessey; gentry_ashley_jo@lilly.com; (317) 416-4363 (Media) Mike Czapar; czapar_michael_c@lilly.com; (317) 617-0983 (Investors) Lilly reports second-quarter 2025 financial results and raises guidance INDIANAPOLIS, August 7, 2025 - Eli Lilly and Company (NYSE: LLY) today announced its financial results for the second-quarter of 2025. "Lilly delivered another quarter of strong performance, achieving 38% year-over-year revenue growth driven by robust s ...

每经AI快讯，8月7日消息，礼来预计财年收入将达到600亿至620亿美元，此前预计为580亿至610亿美 元；礼来预计财年调整后每股收益为21.75美元至23.00美元，此前预计为20.78美元至22.28美元。 ...

Group 1 - The core point of the article is that Eli Lilly (LLY.US) reported a second-quarter adjusted earnings per share of $6.31, up from $3.92 in the same period last year [1] - The company has raised its full-year revenue guidance to between $60 billion and $62 billion, compared to the previous expectation of $58 billion to $61 billion [1]

（文章来源：第一财经） 礼来发布财报，2025年第二季度营收155.6亿美元，同比增长38%。礼来预计全财年营收为600亿至620 亿美元，此前预期为580亿至610亿美元。 ...

INDIANAPOLIS, Aug. 7, 2025 /PRNewswire/ --Eli Lilly and Company (NYSE: LLY) today announced its financial results for the second quarter of 2025. "Lilly delivered another quarter of strong performance, achieving 38% year-over-year revenue growth driven by robust sales of Zepbound and Mounjaro and sustained momentum across our key medicines," said David A. Ricks, Lilly chair and CEO. "Our pipeline continued to advance, highlighted by positive study results in oncology and cardiometabolic health—including Mou ...

| In the first of the county of the | . | | | | | --- | --- | --- | --- | --- | | | [] 和用 Int SEE EX BK JIK 事K 4K 11) 36 59 100 150: 300 1000 2490 3401 5401 Tok 15:110K = | | | ■ 10 - 00 - 10 2 - VS FIO B | | のの日のののののでやったときになったったいと | | | | | | 盘相日前 4316.01万 -- 成绩自美 6.4万 -- 超用价 760.000 | ■但: 645.600 | | | 00 C = 16500 | | 200 000 | | | | 1.82% | | 754.74 | | | | 134% | | PLE PER | | | | 10.85% | | 149.063 | | | | 0.16% | | 145,415 | | | | -0.17% | | 141.760 | | | | 4675 | | 738,122 | | | | (111) | | FREE | | ...